Modified Exosomes Delivering miR-146b for Neurological Injury
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancers like glioblastoma multiforme face challenges in delivering therapeutic microRNAs (miRNAs) efficiently to target cells, as existing methods struggle to effectively absorb and incorporate miRNAs into tissues, limiting their therapeutic potential.
Innovation Solution
The development of a method involving the use of modified exosomes or vesicles containing selected miRNAs, such as miR-146b, produced by transfected mesenchymal stromal cells, which are harvested and administered to patients to target and treat neurological diseases and cancers by delivering therapeutic miRNAs directly to affected cells or tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional miRNA delivery methods are used, then miRNA can be administered to target cells, but the cells cannot efficiently absorb and incorporate significant amounts of miRNA
Solution Approach 1:
The patent uses exosomes as intermediary carriers to deliver miRNA to target cells. Exosomes are natural vesicles that can be harvested from producer cells (such as mesenchymal stromal cells) and contain packaged miRNA. These exosomes serve as a mediator between the miRNA source and target cells, enabling efficient delivery and incorporation of significant amounts of miRNA into target cells, thereby resolving the contradiction between quantity delivered and delivery efficiency
Solution Approach 2:
The patent modifies the physical and chemical parameters of miRNA delivery by encapsulating it within exosomes. This changes the delivery mechanism from direct administration to vesicle-mediated delivery, significantly improving cellular absorption and incorporation efficiency. The exosome membrane and internal environment are optimized to facilitate miRNA protection, cellular uptake, and intracellular release, thereby enhancing both the quantity and reliability of miRNA delivery
2Reliability
If miRNA therapy is developed, then therapeutic benefits can be achieved, but efficient delivery into targeted cells remains a predominant technical challenge
Solution Approach 1:
The patent employs a self-service delivery approach where producer cells (such as mesenchymal stromal cells) naturally produce and secrete exosomes containing therapeutic miRNA. The cells themselves perform the delivery function by releasing exosomes that autonomously navigate to and are taken up by target cells. This self-service mechanism simplifies the overall delivery system architecture compared to engineered delivery vehicles, as it leverages the cell's natural exosome secretion pathway to achieve reliable therapeutic delivery
Solution Approach 2:
The exosome-based delivery system serves multiple functions: it protects miRNA from degradation, facilitates cellular uptake through natural exosome endocytosis pathways, enables targeted delivery to specific cell types, and allows for scalable production through in vitro cell culture. This multi-functional approach consolidates several delivery requirements into a single versatile platform, reducing overall system complexity while maintaining reliable therapeutic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient delivery and incorporation of miRNAs into cells, demonstrating significant anti-tumor effects and potential for treating various neurological diseases and injuries by reducing tumor growth and promoting tissue healing.
Implementation Method 1
harvesting exosomes containing miR-146b microRNA from a cell population capable of producing exosomes containing miR-146b microRNA or media containing the cell population
Implementation Method 2
A predominant technical challenge in developing a miRNA-based therapy is getting target cells to efficiently absorb and incorporate significant amounts of miRNA
Data Source
AI summary
Some embodiments comprise methods, systems, and compositions to produce and/or administer modified exosomes or other vesicles containing one or more selected microRNAs, including but not limited to, miR-146b. Some embodiments also comprise the therapeutic administration and use of such modified exosomes and/or producer cells to treat mammalian brain or neurologic injuries and diseases, including in human beings.